Clinical Trial Update: Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing double-dose Betaferon to the approved dose in early secondary progressive multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Betaferon (interferon beta-1b)

Snippet

Sponsor: Bayer | Conditions: Multiple Sclerosis | Phase 3 | Status: WITHDRAWN